SCHEMBL24845248

SCHEMBL24845248

C[C@H](N)CCCCNC(=O)OCc1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DPP8 Q6V1X1 2/20 0.63
DPP7 Q9UHL4 2/20 0.63
HTT P42858 1/20 0.62
ANPEP P15144 1/20 0.60
FOLH1 Q04609 3/20 0.59
TGM2 P21980 1/20 0.59
SLC1A3 P43003 1/20 0.58
SLC1A1 P43005 1/20 0.58
DPP4 P27487 1/20 0.58
DPP9 Q86TI2 1/20 0.58
LMNA P02545 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
CPB1 P15086 1/20 0.57
CPB2 Q96IY4 1/20 0.57
KEAP1 Q14145 1/20 0.56
NFE2L2 Q16236 1/20 0.56
MMP2 P08253 1/20 0.56
MMP9 P14780 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15177629 1.00 DPP8 (0.63) DPP8DPP7HTTANPEPFOLH1
SCHEMBL13480421 0.96 HTT (0.63) DPP8DPP7HTTANPEPFOLH1
SCHEMBL966186 0.91 HTT (0.55) DPP8DPP7HTTANPEPFOLH1
SCHEMBL19754816 0.90 SLC1A3 (0.66) DPP8DPP7HTTANPEPTGM2
Hydrochloric Acid SCHEMBL28665675 0.89 SLC1A3 (0.64) DPP8DPP7HTTANPEPTGM2
SCHEMBL13251388 0.89 HTT (0.65) DPP8DPP7HTTANPEPFOLH1
SCHEMBL19976515 0.88 TGM2 (0.64) DPP8DPP7HTTANPEPFOLH1
SCHEMBL10917494 0.87 DPP8 (0.64) DPP8DPP7HTTANPEPFOLH1
SCHEMBL23542526 0.87 DPP8 (0.64) DPP8DPP7HTTANPEPFOLH1
SCHEMBL14194799 0.87 HTT (0.59) DPP8DPP7HTTANPEPFOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240279233-A1 MACROCYCLIC TAK1 INHIBITORS AQILION AB (SE) 2024-08-22 US disclosed
EP-4363422-A1 MACROCYCLIC TAK1 INHIBITORS Aqilion AB (SE) 2024-05-08 EP disclosed
WO-2023275199-A1 MACROCYCLIC TAK1 INHIBITORS AQILION AB (SE) 2023-01-05 WO disclosed
WO-2023275199-A1 MACROCYCLIC TAK1 INHIBITORS AQILION AB (SE) 2023-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279233-A1 MACROCYCLIC TAK1 INHIBITORS TAB1, TBK1, IRAK3 DPP8 3601/4885DPP7 3815/4885HTT 2383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.